Market Cap 220.91M
Revenue (ttm) 0.00
Net Income (ttm) -69.68M
EPS (ttm) N/A
PE Ratio 16.35
Forward PE 10.74
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 487,000
Avg Vol 920,046
Day's Range N/A - N/A
Shares Out 56.94M
Stochastic %K 33%
Beta 3.07
Analysts Strong Sell
Price Target $9.50

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 252 0848
Address:
One Main Street, 14th Floor, Cambridge, United States
garbageshort
garbageshort Oct. 22 at 4:13 PM
$BDTX next stop is 2.50 as I promised u guys
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 2:29 PM
$SNDX , $BDTX , $RVMD , $VSTM , $NUVL ... H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments. https://notreload.xyz/sndx-bdtx-rvmd-vstm-nuvl-buy-ratings/
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:50 PM
Stifel has adjusted their stance on Black Diamond Therapeutic ( $BDTX ), setting the rating to Buy with a target price of 8.
1 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 1:51 PM
$BDTX up 75.7% YTD — undervalued or overhyped? 🚀 Despite competitive pressure from big players like $AZN and $JNJ in the NSCLC space, BDTX trades at just 1.61x book value, well below the biotech industry average of 3.36x. Opportunity or risk? Dive deeper here 👉 https://www.zacks.com/stock/news/2769115/can-nsclc-drug-silevertinib-drive-sustainable-growth-for-bdtx?cid=sm-stocktwits-2-2769115-body-16120&ADID=SYND_STOCKTWITS_TWEET_2_2769115_BODY_16120
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 12:51 PM
$BDTX pivots hard toward silevertinib — can one NSCLC drug fuel lasting growth? The biotech just outlicensed its other lead asset to Servier, putting full focus on silevertinib, its next-gen EGFR inhibitor for NSCLC. Full growth thesis here 👉 https://www.zacks.com/stock/news/2769115/can-nsclc-drug-silevertinib-drive-sustainable-growth-for-bdtx?cid=sm-stocktwits-2-2769115-teaser-16118&ADID=SYND_STOCKTWITS_TWEET_2_2769115_TEASER_16118
0 · Reply
garbageshort
garbageshort Oct. 14 at 4:46 PM
$BDTX need to travel back to 2.50 to kick retail out
1 · Reply
Invest2live
Invest2live Oct. 13 at 7:20 PM
$BDTX $BITF $SKYT $SKYT $98% already; congrats 🎉 🎈🎊 Checkout $TDOC
0 · Reply
100K2022
100K2022 Oct. 13 at 6:47 PM
$BDTX come on beautiful back over 4
0 · Reply
Nunotrader
Nunotrader Oct. 13 at 4:06 PM
0 · Reply
Nunotrader
Nunotrader Oct. 13 at 1:49 PM
0 · Reply
Latest News on BDTX
Black Diamond Therapeutics: In Decline, But Why?

Mar 13, 2025, 3:47 PM EDT - 8 months ago

Black Diamond Therapeutics: In Decline, But Why?


Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy


Black Diamond Therapeutics Announces CEO Transition

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition


garbageshort
garbageshort Oct. 22 at 4:13 PM
$BDTX next stop is 2.50 as I promised u guys
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 2:29 PM
$SNDX , $BDTX , $RVMD , $VSTM , $NUVL ... H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments. https://notreload.xyz/sndx-bdtx-rvmd-vstm-nuvl-buy-ratings/
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:50 PM
Stifel has adjusted their stance on Black Diamond Therapeutic ( $BDTX ), setting the rating to Buy with a target price of 8.
1 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 1:51 PM
$BDTX up 75.7% YTD — undervalued or overhyped? 🚀 Despite competitive pressure from big players like $AZN and $JNJ in the NSCLC space, BDTX trades at just 1.61x book value, well below the biotech industry average of 3.36x. Opportunity or risk? Dive deeper here 👉 https://www.zacks.com/stock/news/2769115/can-nsclc-drug-silevertinib-drive-sustainable-growth-for-bdtx?cid=sm-stocktwits-2-2769115-body-16120&ADID=SYND_STOCKTWITS_TWEET_2_2769115_BODY_16120
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 12:51 PM
$BDTX pivots hard toward silevertinib — can one NSCLC drug fuel lasting growth? The biotech just outlicensed its other lead asset to Servier, putting full focus on silevertinib, its next-gen EGFR inhibitor for NSCLC. Full growth thesis here 👉 https://www.zacks.com/stock/news/2769115/can-nsclc-drug-silevertinib-drive-sustainable-growth-for-bdtx?cid=sm-stocktwits-2-2769115-teaser-16118&ADID=SYND_STOCKTWITS_TWEET_2_2769115_TEASER_16118
0 · Reply
garbageshort
garbageshort Oct. 14 at 4:46 PM
$BDTX need to travel back to 2.50 to kick retail out
1 · Reply
Invest2live
Invest2live Oct. 13 at 7:20 PM
$BDTX $BITF $SKYT $SKYT $98% already; congrats 🎉 🎈🎊 Checkout $TDOC
0 · Reply
100K2022
100K2022 Oct. 13 at 6:47 PM
$BDTX come on beautiful back over 4
0 · Reply
Nunotrader
Nunotrader Oct. 13 at 4:06 PM
0 · Reply
Nunotrader
Nunotrader Oct. 13 at 1:49 PM
0 · Reply
Invest2live
Invest2live Oct. 11 at 3:09 PM
$NOK 23% already; congrats 🎈🎉🎊🌿 Checkout $BDTX and $VTEX
0 · Reply
Adamchristlover
Adamchristlover Oct. 9 at 9:59 PM
$BDTX $CAPR $CRBU $ASYS I made a lot of money with you thanks Jack
0 · Reply
100K2022
100K2022 Oct. 9 at 7:44 PM
$BDTX anyone adding here?
0 · Reply
Jafo333isme
Jafo333isme Oct. 9 at 7:23 PM
$BDTX I'll take it! Was a best kept bio secret for a while - but we have been discovered. LOL. Still, the board is nice and quiet and free from penny pinchers/shorts/scammers/FUDsters.
0 · Reply
Dynotro81
Dynotro81 Oct. 9 at 6:45 PM
$BDTX steady climb, $5+ soon
0 · Reply
StockRegulationBot
StockRegulationBot Oct. 9 at 6:39 PM
$BDTX Fantastic. Come on $6.50++ I'll be exiting the position there. Should it falter at earnings or prior to, I'll have to rethink my exit strategy. See you all at $6.50.
1 · Reply
Nb713
Nb713 Oct. 9 at 5:08 PM
$BDTX steady rising 😎
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 4:48 PM
Results list 9/26/25 $BDTX $BDX $BE $BEKE 🔥 Cycle Trading Signal plugged into AI list 🔥
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 4:38 PM
$BDTX hits a 52-week high — what’s driving this biotech rocket? 🚀 Silevertinib, its lead drug, shows promising results in targeting EGFRm NSCLC. BDTX shares have 86.4% YTD growth, outpacing the industry’s 10.4%. With a Zacks Rank #1 (Strong Buy), BDTX is one to watch! Find out what could drive BDTX’s next breakout 👉 https://www.zacks.com/stock/news/2765547/bdtx-stock-hits-52-week-high-is-there-more-room-for-growth?cid=sm-stocktwits-2-2765547-body-15425&ADID=SYND_STOCKTWITS_TWEET_2_2765547_BODY_15425
0 · Reply
zackopaw
zackopaw Oct. 9 at 2:58 PM
$PYXS $BDTX m out from both. Too much profit for me. Need to enjoy money also
1 · Reply
StockRegulationBot
StockRegulationBot Oct. 9 at 2:40 PM
$BDTX Hoping Guggenheim guy is correct. The derivatives paint a $2.50-$3.00 bullseye for max pain, with far overpriced risk to value. Heavy premiums collected if it dies on the vine. If December targets are delayed/fail, what sort of fallout do we expect? Negative earnings report compared to prior quarter. There's no paid milestones announced, to be paid for that data/result either. Let's push for $4.75+ $5 range for support, in the next 3 weeks. If the vampires show up in league with delayed data, or a fail, then a beat back to the $2.75 - $3.25 range could be a week of daily 10-15% drops in a row. Back under $3 potentially. That same pattern for the massive bull traps. I'd like to see this close over $5 for sure, prior to earnings. With certainty, we have a safety net around $3. There's just no way I move from $2.50 to $5 options and pay either premium without getting my head checked; until the price is well above $5. Less than 30 days until quarter results will post.
1 · Reply
jacksparo
jacksparo Oct. 9 at 12:08 AM
$BDTX $CAPR $CRBU $ASYS All from my email alerts and made it to entry/exit Full marks 💯 Successful in the last few weeks ✅✅✅!
2 · Reply